Literature DB >> 26819280

ATAD2 overexpression is associated with progression and prognosis in colorectal cancer.

Mingming Hou1, Rui Huang2, Yanni Song3, Di Feng4, Yang Jiang4, Ming Liu5.   

Abstract

OBJECTIVES: ATPase family AAA domain-containing 2 plays an important role in tumor progression including cell cycle, proliferation, apoptosis and chemoresistance. However, the expression of ATPase family AAA domain-containing 2 in colorectal cancer and its significance are still unclear. The aim of this study was to examine the expression of ATPase family AAA domain-containing 2 in colorectal cancer.
METHODS: Immunohistochemistry was used to determine the expression of ATPase family AAA domain-containing 2 in 155 colorectal cancer and 30 matched adjacent noncancerous tissues. The correlation of ATPase family AAA domain-containing 2 expression with clinicopathological variables was assessed using chi-square test. Patient survival was analyzed using the Kaplan-Meier and log-rank tests. Cox regression was performed for the multivariate analysis of prognostic factors.
RESULTS: High expression of ATPase family AAA domain-containing 2 was detected in 58.1% of the colorectal cancers and was significantly associated with advanced tumor-node-metastasis stage (P = 0.044), poor differentiation (P = 0.028), deep infiltration (P < 0.001), lymphovascular invasion (P = 0.006), lymph node metastasis (P = 0.024) and recurrence (P = 0.022). Patients with high ATPase family AAA domain-containing 2 expression had significantly poorer overall survival and disease-free survival (both P < 0.001) when compared with patients with low expression of ATPase family AAA domain-containing 2. The multivariate analysis showed that ATPase family AAA domain-containing 2 was an independent factor for both overall survival (P = 0.003; hazard ratio (HR): 2.356; 95% confidence interval (CI): 1.335-4.158) and disease-free survival (P = 0.001; HR: 2.643; 95% CI: 1.489-4.693).
CONCLUSIONS: These results showed that ATPase family AAA domain-containing 2 overexpression was associated with progression and prognosis of colorectal cancer.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  ATAD2; colorectal cancer; immunohistochemistry; prognosis

Mesh:

Substances:

Year:  2016        PMID: 26819280     DOI: 10.1093/jjco/hyv195

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  12 in total

1.  Disulfide bridge formation influences ligand recognition by the ATAD2 bromodomain.

Authors:  Jamie C Gay; Brian E Eckenroth; Chiara M Evans; Cassiano Langini; Samuel Carlson; Jonathan T Lloyd; Amedeo Caflisch; Karen C Glass
Journal:  Proteins       Date:  2018-12-27

2.  Structural Insights into the Recognition of Mono- and Diacetylated Histones by the ATAD2B Bromodomain.

Authors:  Jonathan T Lloyd; Kyle McLaughlin; Mulu Y Lubula; Jamie C Gay; Andrea Dest; Cong Gao; Margaret Phillips; Marco Tonelli; Gabriel Cornilescu; Matthew R Marunde; Chiara M Evans; Samuel P Boyson; Samuel Carlson; Michael-Christopher Keogh; John L Markley; Seth Frietze; Karen C Glass
Journal:  J Med Chem       Date:  2020-10-21       Impact factor: 7.446

Review 3.  Bromodomain inhibitors and cancer therapy: From structures to applications.

Authors:  Montserrat Pérez-Salvia; Manel Esteller
Journal:  Epigenetics       Date:  2016-12-02       Impact factor: 4.528

4.  Human germ/stem cell-specific gene TEX19 influences cancer cell proliferation and cancer prognosis.

Authors:  Vicente Planells-Palop; Ali Hazazi; Julia Feichtinger; Jana Jezkova; Gerhard Thallinger; Naif O Alsiwiehri; Mikhlid Almutairi; Lee Parry; Jane A Wakeman; Ramsay J McFarlane
Journal:  Mol Cancer       Date:  2017-04-26       Impact factor: 27.401

5.  Long Non-Coding RNA CRNDE Promotes Colorectal Carcinoma Cell Progression and Paclitaxel Resistance by Regulating miR-126-5p/ATAD2 Axis.

Authors:  Chang Liu; Jianfeng Hou; Fengxiao Shan; Lijuan Wang; Hanjie Lu; Tiejun Ren
Journal:  Onco Targets Ther       Date:  2020-06-02       Impact factor: 4.147

6.  Overexpression of ATAD2 indicates Poor Prognosis in Oral Squamous Cell Carcinoma.

Authors:  Xiao-Long Wang; Shuo Wang; Zhi-Zhong Wu; Qi-Chao Yang; Hao Li; Hong-Gang Xiong; Shu-Cheng Wan; Zhi-Jun Sun
Journal:  Int J Med Sci       Date:  2020-06-27       Impact factor: 3.738

7.  Prognostic value of ATPase family, AAA+ domain containing 2 expression in human cancers: A systematic review and meta-analysis.

Authors:  Hua-Jing Han; Qian-Yi Huang; Li-Jun Huang; Fan Chang; Qi-Zhi Diao
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

8.  MicroRNA-372 functions as a tumor suppressor in cell invasion, migration and epithelial-mesenchymal transition by targeting ATAD2 in renal cell carcinoma.

Authors:  Shiqi Ji; Xiaolin Su; Haijian Zhang; Zhixing Han; Yuqian Zhao; Qingjun Liu
Journal:  Oncol Lett       Date:  2018-12-28       Impact factor: 2.967

9.  A Humanized Yeast Phenomic Model of Deoxycytidine Kinase to Predict Genetic Buffering of Nucleoside Analog Cytotoxicity.

Authors:  Sean M Santos; Mert Icyuz; Ilya Pound; Doreen William; Jingyu Guo; Brett A McKinney; Michael Niederweis; John Rodgers; John L Hartman
Journal:  Genes (Basel)       Date:  2019-09-30       Impact factor: 4.096

10.  Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma.

Authors:  Xiangyu Meng; Lu Wang; Bo Zhu; Jun Zhang; Shuai Guo; Qiang Li; Tao Zhang; Zhichao Zheng; Gang Wu; Yan Zhao
Journal:  Biomed Res Int       Date:  2020-05-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.